Risk factors for cervical cancer in China: a case-control study

Objectives: To determine the prevalence of human papillomavirus types and investigate the risk factors for cervical cancer in Hubei, China. Methods: We conducted a case-control study to investigate risk factors. Results: HPV DNA was detected in 94.55% of patients with cervical carcinoma, and 23.64% of control subjects. The most common HPV type in cervical cancer was HPV type 16 (81.82%), followed by HPV 58 (6.36%). HPV infected patients have a higher risk of developing cervical carcinoma, which is 75.79 times more than non-infected people. The other risks were age at first intercourse (p = 0.017) and number of live births (p = 0.032). A history of previous cytologic screening was associated with a substantial reduction in risk (p = 0.001). Conclusions: The three principal reasons that Hubei has a high rate of women developing cervical carcinoma are HPV infection, age at first sexual intercourse and number of live births. Cervical cytology screening provides efficacious protection.

Cervical cancer; Risk factors; Case-control study; HPV

[1] IARC monographs on the evaluation of carcinogenic risks to humans. In: Human papillomavirus viruses. International Agency Research on Cancer, Lyon, 1995, 64, 96.

[2] Bosch F.X., Manos M.M., Munoz N., Munoz N., Sherman M., Jansen A.M. et al.: “Prevalence of human papillomavirus in cervical cancer: A worldwide perapective”. JNCI, 1995, 87, 796.

[3] Anderson S., Rylander E., Larsson B., Strand A., Silfversvard C., Wilander E.: “The role of human papillomavirus in cervical adeocarcinoma carcinogenesis”. Eur. J. Cancer, 2001, 37, 246.

[4] Cau-sen L.: “Advantage on epideminology and etiology research of cervical carcinoma”. J. Pract. Obstet. Gynecol., 1994, 10, 229.

[5] De Sanjose S., Bosch F.X., Muñoz N., Tafur L., Gili M., Izarzugaza I. et al.: “Socieconomic differences in cervical cancer: Two case-control study in Colombia and Spain”. Am. J. Public Health, 1996, 86, 1532.

[6] Hall S., Lorincz A., Shah F., Sherman M.E., Abbas F., Paull G. et al.: “Human papillomavirus DNA detection in cervical specimens by Hybrid Capture: correlation with cytologic and histologic diagnoses of squamous intraepithelial lesions of cervix”. Gynecol. Oncol., 1996, 62, 353.

[7] Wilson H.G., Curtis K.M., Marchbanks P.A.: “Parity, age at first birth, and risk of invasive cervical cancer: Meta-analyses”. Ann. Epidemiol., 2002, 12, 490.

[8] Rostad B., Schei S., da Costa F.: “Risk factors for cervical cancer in Mozambican women”. Int. J. Gynecol. Obstert., 2003, 80, 63.

[9] Steckley S.L., Pickworth W.B., Haverkos H.W.: “Cigarette smoking and cervical cancer, Part II: A geograghic variability study”. Biomed. Pharmacother., 2003, 57, 78.

[10] Haverkos H., Rohrer M., Pickworth W.: “The cases of invasive cervical cancer could be multifactorial”. Biomed. Pharmacother., 2000, 54, 54.

[11] Moreno V., Bosch F.X., Muñoz N., Meijer C.J.L.M., Shah D.V., Valboomers J.M.M. et al.: “Effect of oral contraceptives on risk of cervical cancer in women with human papillomavieus infection: the IARC multicentric case-control study”. Lancet, 2002, 359, 1085.

[12] Yoo K.Y., Kang D., Koo H.W., Park S.K., Kim D.H., Park N.H. et al.: “Risk factors associated with uterine cervical cancer in Korea: a case-control study with special reference to sexual behavior”. J. Epidemiol., 1997, 7, 117.

[13] Villa L.L., Sichero L., Rahal P., Caballero O., Ferency A., Rohan T. et al.: “Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia”. J. General. Virology, 2000, 81, 2959.

[14] Wu Y., Chen Y., Li L., Yu G., Zhang Y., He Y.: “Associations of high-risk HPV types and viral load with cervical cancer in China”. J. Clin. Vir., 2006, 35, 264.

[15] Clifford G.M., Smith J.S., Plummer M., Muioz N., Franceschi S.: “Human papillomavirsue types in invasive cervical cancer worldwide: a meta-analysis”. Br. J. Cancer, 2003, 88, 36.

[16] Munoz N., Bosch F.X., Bosch F.X., de Sanjose S., Herrero R., Castellsague X. et al.: “Epidemiologic classification of human papillomavirus types associated with cervical cancer”. The New Engl. J. Med., 2003, 348, 518.

[17] Huang S., Afonina I., Miller B.A., Beckman A.M.: “Human papillomavirus types 52 and 58 are prevalent in cervical infection in young women”. Int. J. Cancer, 1997, 70, 408.

[18] Chen C.A., Liu C.Y., Chou H.H., Chou C.Y., Ho C.M., Twu N.F., et al.: “The distribution and differential risk of human papillomavirus genotypes in cervical preinvasive lesions: a Taiwan Cooperative Oncologic Group Study”. Int. J. Cancer, 2006, 16, 1801.

[19] Munoz N., Bosch F.X., de Sanjose S., Tafur L., Izarzugaza I., Gili M. et al.: “The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain”. Int. J. Cancer, 1992, 52, 743.

[20] Eluf-neto J., Booth M., Munoz N., Bosch F.X., Meijer C.J., Walboomers J.M.: “Human papillomavirus and invasive cervical cancer in Brazil”. Br. J. Cancer, 1994, 69, 114.

[21] Bosch F.X., Munoz N., de Sanjose S., Navarro C., Moreo P., Ascunce N. et al.: “Human papillomavirus and cervical intraepithelial neoplasia grade III carcinoma in situ: a case-control study in Spain and Colombia”. Cancer Epidemiol. Biomarkers Prev., 1993, 2, 415.

[22] Bosch F.X., Munoz N., de Sanjose S., Izarzugaza I., Gili M., Viladiu P. et al.: “The risk factors for cervical cancer in Colombia and Spain”. Int. J. Cancer, 1992, 52, 750.

[23] Chichareon S., Herrero R., Munoz N., Bosch F.X., Jacobs M.V., Deacon J. et al.: “Risk factors for cervical cancer in Thailand: a Case-control study”. J. Int. Cancer Inst., 1998, 90, 50.

[24] Ngelangel C., Munoz N., Bosch F.X., Limson G.M., Festin M.R., Deacon J. et al.: “Causes of cervical cancer in the Philippines: a Case-control study”. J. Int. Natl., 1998, 90, 43.